Article Details
Retrieved on: 2022-06-05 12:56:53
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Starpharma has a chunky $300m valuation that looks reasonable considering AstraZeneca is likely to spend $US100m on trials.
Article found on: stockhead.com.au
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here